Cosmos Health Inc. $COSM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Wholesale-Drugs, Proprietaries & Druggists' Sundries
- Headquarters
- Thessaloniki, Greece
- Fiscal year end
- December 31
- Shares outstanding
- 100,633,773 [10-Q 2026-08-18]
What the company doesAI summary of filing
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company that develops, manufactures, and distributes pharmaceutical and nutraceutical products. The company generates revenue through multiple business segments: generic medicines (therapeutic equivalents of branded drugs sold at lower prices), proprietary nutraceutical brands (Sky Premium Life and Mediterranation), biocides and antiseptic products (C-Sept and C-Scrub), pharmaceutical manufacturing for third parties under GMP/EMA certification, wholesale pharmaceutical distribution to pharmacies and hospitals, and a telehealth platform (ZipDoctor). The company is also developing novel medicines through research and development activities, including obesity treatment CCX0722, cancer treatments targeting CNS, prostate, ovarian and colorectal cancers, and operates an AI-powered drug repurposing platform (Cloudscreen). Cosmos Health is revenue-generating, with the majority of revenues currently from European Union operations, particularly Greece, with growing contributions from the UAE and initial U.S. operations commencing in 2026. [10-K 2026-04-15]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $36.91M | −$8.89M | −$2.79M | $1.80M | [10-Q 2026-08-18] |
| FY ended Dec 2025 | $65.27M | −$19.14M | −$8.45M | $715.7K | [10-K 2026-04-15] |
| FY ended Dec 2024 | $54.43M | −$16.18M | −$7.72M | $315.1K | [10-K 2026-04-15] |
- Quarterly cash burn
- −$1.39M
- Cash runway Estimate
- ~3.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-14 | 23,346,049 | [10-Q 2024-11-14] |
| 2025-04-15 | 27,284,658 | [10-K 2025-04-15] |
| 2025-05-15 | 28,751,422 | [10-Q 2025-05-15] |
| 2025-08-14 | 30,213,876 | [10-Q 2025-08-18] |
| 2025-11-14 | 34,919,920 | [10-Q 2025-11-14] |
| 2026-04-14 | 50,824,657 | [10-K 2026-04-15] |
| 2026-05-18 | 54,428,491 | [10-Q 2026-05-20] |
| 2026-08-18 | 100,633,773 | [10-Q 2026-08-18] |
- Shelf registration
- S-3 filed 2025-11-07; no effectiveness notice found in EDGAR [S-3 2025-11-07]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-12-18. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-12-18 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-12-18] |
| 2025-05-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-05-07] |
| 2024-11-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-12] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-30 | Siokas Grigorios | buy | 349,825 | $0.20 | [4 2026-07-31] |
| 2026-07-29 | Terzis Georgios | grant | 328,407 | $0.18 | [4 2026-07-30] |
| 2026-07-29 | Siokas Grigorios | buy | 766,284 | $0.18 | [4 2026-07-30] |
| 2026-06-16 | Terzis Georgios | buy | 168,135 | $0.25 | [4 2026-06-17] |
| 2026-06-11 | Siokas Grigorios | buy | 218,447 | $0.21 | [4 2026-06-12] |
| 2026-06-10 | Siokas Grigorios | buy | 701,447 | $0.23 | [4 2026-06-12] |
| 2026-05-19 | Karkantzos Theodoros Christos | grant | 20,000 | $0.28 | [4 2026-06-11] |
| 2026-05-19 | Hoidas John James | grant | 20,000 | $0.28 | [4 2026-06-11] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-09 | 8-K | Results of operations |
| 2026-08-20 | 8-K | Results of operations |
| 2026-08-18 | 10-Q | Quarterly report |
| 2026-08-14 | NT 10-Q | Notice of late quarterly report |
| 2026-07-16 | 8-K | Change to security holder rights; Director or officer change; Charter, bylaws or fiscal year change |
| 2026-07-06 | 8-K | Regulation FD disclosure; Other events |
| 2026-06-08 | S-3/A | Registration statement |
| 2026-06-05 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-06-02 | DEF 14A | Proxy statement |
| 2026-05-22 | PRE 14A | Proxy statement |
| 2026-05-22 | 8-K | Results of operations |
| 2026-05-20 | 10-Q | Quarterly report |
Alerts for $COSM
Email me when Cosmos Health Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.